• The Wear It Out program was created with and for patient advocates to reduce stigma and increase awareness of the everyday, often unseen compromises and decisions people make because of their conditions.

• Artist Sophia Yeshi brought real stories of people living with HS, PSO, and PsA to life in the form of a t-shirt, transforming them into a wearable expression of connection and self-expression.

• If you’re living with HS, PSO, or PsA, visit GoWearItOut.com to learn how to submit your story, join the community, and receive your one-of-a-kind Wear It Out t-shirt.

   

Atlanta, October 13, 2026 – 09:00 (EST) – UCB, a global biopharmaceutical company, today announced the launch of Wear It Out, a program created with and for people living with hidradenitis suppurativa (HS), plaque psoriasis (PSO), and psoriatic arthritis (PsA). Together, these conditions affect millions of people in the U.S., with approximately 2.5 million people living with HS, and approximately 11.3 million people living with PSO or PsA. Developed alongside patient advocates and acclaimed artist Sophia Yeshi, the Wear It Out program showcases the everyday, often unseen decisions and compromises people make because of their conditions.

Wear It Out was born from listening to the community and recognizing a shared desire to feel seen, understood, and empowered. For many people living with HS, PSO, and PsA, the impact of disease extends beyond physical symptoms, shaping the choices other people often take for granted, like what to wear. For some living with HS, white clothing may feel off limits because drainage or leakage from a flare could show. For those living with PSO, black clothing can make flaking more visible, while PsA symptoms, such as stiff or painful joints, can make getting dressed, including fastening buttons, more difficult.

“Getting dressed should not be a strategic decision, and feeling comfortable in your own body should never feel out of reach, but for many people with HS, PSO, or PsA, it can be–quietly ruling out a white or black shirt or skipping an invitation because of what the condition may show,” said Brittany Blair, Head of Patient Strategy, U.S. Immunology, UCB. “Wear It Out transforms that quiet calculation into a visual community symbol worth celebrating and it is a reminder that no one should have to settle for less than feeling like themselves in their healthcare journey.”

At the center of Wear It Out is a collection of one-of-a-kind, condition-conscious t-shirts, which reclaim those familiar colors as symbols of the choices others may never understand. Inspired by the real stories of people living with HS, PSO, and PsA, and brought to life by Brooklyn-based graphic designer and illustrator Sophia Yeshi, each t-shirt design transforms lived experiences into a wearable expression of connection and self-expression. White and black tees are no longer just everyday wardrobe staples, but reminders that the experiences behind them deserve to be recognized.

“My work explores themes of identity, resilience, and belonging, so when I was given the opportunity to create something beautiful out of the often challenging experiences of real people living with these conditions, I was so inspired,” said Sophia Yeshi, graphic designer and illustrator at Yeshi Designs. Every person who shared their story brought a unique perspective and sense of strength to this project. My goal was to create artwork that honors those experiences and reflects the beauty, courage, and individuality of the community, and thanks to the patients and advocates involved, I think we achieved that.”

Through shared experiences, community storytelling, and opportunities for connection, the program encourages individuals to celebrate the moments that matter most, whether that means wearing a color they once avoided, reconnecting with loved ones, saying yes to new opportunities, or simply showing up with greater confidence.

HS, PSO, and PsA community members can visit GoWearItOut.com to join the Wear It Out community, receive resources, and share their own story via video or audio to receive a condition-conscious t-shirt.

For further information, contact UCB:

Investor Relations
Yvonne Naughton
T: +44.175.344.7521
Email: Yvonne.Naughton@ucb.com

Sahar Yazdian
T: +32.2.559.91.37
Email: Sahar.Yazdian@ucb.com

Corporate Communications 
Laurent Schots  
T: +32.2.559.92.6
Email: Laurent.Schots@ucb.com

U.S. Communications
Nicole Herga
T +1.773.960.5349
Email: Nicole.Herga@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of $ 7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB)

Forward-looking statements
This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB’s information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.
Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.